Trevi Therapeutics (TRVI) Current Assets (2018 - 2026)

Trevi Therapeutics' Current Assets history runs 9 years deep, the most recent figure standing at $176.1 million for Q1 2026.

• On a quarterly basis, Current Assets rose 66.75% year-over-year to $176.1 million in Q1 2026; TTM through Mar 2026 was $176.1 million, a 66.75% increase from a year earlier, with the FY2025 full-year figure at $191.7 million, up 75.14% from the prior year.
• Current Assets fell to $176.1 million in Q1 2026 per TRVI's latest filing, from $191.7 million in the prior quarter.
• Across five years, Current Assets topped out at $207.2 million in Q2 2025 and bottomed at $29.8 million in Q1 2022.
• The 5-year median for Current Assets is $105.6 million (2025), against an average of $115.2 million.
• Across the five-year window, Current Assets soared 314.62% in 2022 and sank 32.78% in 2024, its largest moves.
• Year by year, Current Assets stood at $122.6 million in 2022, then dropped by 28.6% to $87.5 million in 2023, then gained by 24.99% to $109.4 million in 2024, then jumped by 75.14% to $191.7 million in 2025, then declined by 8.11% to $176.1 million in 2026.
• Per Business Quant, the three latest TRVI Current Assets figures stand at $176.1 million (Q1 2026), $191.7 million (Q4 2025), and $198.3 million (Q3 2025).